H.W. Andersen boosting Sterijet marketing following validation of device sterilization system.
This article was originally published in The Gray Sheet
H.W. ANDERSEN'S COURT REQUEST FOR MORE TIME TO VALIDATE STERILIZATION procedure enabled the company to fend off an FDA complaint for injunction. The U.S. District Court in Greensboro, North Carolina dismissed FDA's complaint earlier this year after finding that the privately held Haw River, North Carolina-based firm had addressed all the deficiencies cited by FDA for validation of its Sterijet technique.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.